STAT3 and myeloid sarcoma: Notably, in the context of MS, ANGPT1 is regulated by key immune-modulatory TFs such as PPARG and STAT3, where PPARG mediates anti-inflammatory responses and ameliorates disease progression, while STAT3 promotes pro-inflammatory Th17 differentiation and neuroinflammation65.